
9 Apr 2025
TRAILBLAZER-ALZ Trial Data Reveals Donanemab Effects in Early Alzheimer's: AAN 2025
At the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego, new data from the TRAILBLAZER-ALZ clinical trial program highlighted critical risk factors and management strategies for amyloid-related imaging abnormalities (ARIA) in patients with early symptomatic Alzheimer’s disease treated with donanemab.

9 Apr 2025
Landmark Migraine Study Identifies 778 Genetic Risk Variants in Veterans: AAN 2025
A genome-wide association study (GWAS) presented at the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego has identified 778 previously unknown genetic variants associated with migraine, shedding new light on the condition’s genetic underpinnings across racial and ethnic groups.